Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library

Sim, Derek S.; Shukla, Meenal; Mallari, Cornell R; Fernández, José A.; Xu, Xiao; Schneider, Doug; Bauzon, Maxine; Hermiston, Terry; Mosnier, Laurent O.

doi:10.1182/bloodadvances.2022008740

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APC is responsible for coagulation homeostasis as it prevents hypercoagulability of the blood. Thrombin, which is the final product of coagulation, activates factors that precede it at different levels of the cascade and also reacts with APC through TM [ 84 , 85 , 86 ].…”

Section: Factor V a Procoagulant And Anticoagulant Proteinmentioning

confidence: 99%

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

Pablo-Moreno

Miguel-Batuecas

Sancha

et al. 2023

IJMS

View full text Add to dashboard Cite

Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.

show abstract

Section: Factor V a Procoagulant And Anticoagulant Proteinmentioning

confidence: 99%